


FGF23 (C-terminal)
multi-matrix **ELISA**



First FGF23 (C-terminal) assay
for both serum & plasma samples

Fully validated

Setting the **standard**
for **clinical** research.




Features and Benefits

- MULTI-MATRIX ASSAY – for serum and plasma samples (EDTA, heparin, citrate)
- HIGHLY SENSITIVE – clear differentiation even at low serum FGF23 levels
- STANDARDIZED QUANTIFICATION in pmol/l
- FULLY VALIDATED for serum and plasma – according to ICH Q2
- SERUM BASED STANDARDS and CONTROLS – for biologically reliable data
- LOW SAMPLE VOLUME – only 50 µl of sample required
- CONVENIENT PROTOCOL – all reagents included


Assay Characteristics

- Method: Sandwich ELISA, HRP/TMB, 12x8-well strips
- Sample type: Serum and plasma (EDTA, heparin, citrate)
- Sample size: 50 µl / test
- Standard range: 0 – 20 pmol/l (7 serum based standards + 2 controls)
- Sensitivity: LOD: 0.08 pmol/l, LLOQ: 0.1 pmol/l
- Specificity: The assay incorporates two affinity purified polyclonal antibodies that recognize epitopes located within the C-terminal region of FGF23.
- Incubation: 20-24 h / 1 h / 30 min
- Unit conversion: 1 pg/ml = 0.133 pmol/l (MW: 7.52 kDa)

Typical Standard Curve



FGF23 (C-terminal) Levels in Serum and Plasma



Spike/Recovery

Matrix	n	Mean S/R [%]	
		+5 pmol/l	+10 pmol/l
Serum	13	96	89
EDTA plasma	8	91	89
Heparin plasma	8	101	92
Citrate plasma	8	106	95

Dilution Linearity

Matrix	n	R of dilution steps [%]		
		1+1	1+3	1+7
Serum	9	105	100	108
EDTA plasma	4	103	103	106
Heparin plasma	10	107	106	104
Citrate plasma	4	119	n.a.	n.a.

SPECIFICITY

The assay measures both intact FGF23 and C-terminal fragments of FGF23.

The FGF23 detected in this assay is stable after sample collection. The assay can be used for all sample types.

Related Biomedica Products

- Sclerostin ELISA, Cat.No. BI-20492
- FREE soluble RANKL ELISA, Cat.No. BI-20462
- DKK-1 ELISA, Cat.No. BI-20413
- Osteoprotegerin ELISA, Cat.No. BI-20403